Chapter 42: Chronic Glomerular Diseases – Complete Educational Package
Learning Objectives
By the end of this chapter, learners will be able to:
1. Understand the general principles and classification of chronic glomerular diseases.
2. Differentiate between common chronic glomerular diseases based on their pathophysiology, clinical presentation, and biopsy findings.
3. Discuss the diagnostic approach to chronic glomerular diseases, including serological markers and renal biopsy.
4. Outline the general management strategies for chronic glomerular diseases, including immunosuppression and supportive care.
5. Recognize the long-term complications and prognosis associated with chronic glomerular diseases.
42.1 Introduction to Chronic Glomerular Diseases
Chronic glomerular diseases (CGD) represent a diverse group of kidney disorders characterized by persistent inflammation and damage to the glomeruli, the kidney’s filtering units. Unlike acute glomerulonephritis, CGD often progresses slowly over years, leading to proteinuria, hematuria, hypertension, and ultimately, chronic kidney disease (CKD) and end-stage renal disease (ESRD). Early diagnosis and appropriate management are crucial to slow disease progression and preserve renal function.
42.2 Classification and Pathophysiology
CGD can be primary (affecting only the kidney) or secondary (part of a systemic disease). The pathophysiology often involves immune-mediated mechanisms leading to glomerular injury.
Common Chronic Glomerular Diseases:
-
Focal Segmental Glomerulosclerosis (FSGS):
- Pathophysiology: Sclerosis (scarring) of some glomeruli (focal) and only parts of those glomeruli (segmental). Involves podocyte injury and detachment. Can be primary (idiopathic) or secondary (e.g., genetic, viral infections like HIV, drug-induced, adaptive from nephron loss).
- Clinical Presentation: Often presents with nephrotic syndrome (heavy proteinuria, hypoalbuminemia, edema, hyperlipidemia), but can also have non-nephrotic proteinuria.
- Prognosis: Variable, but often progressive to ESRD, especially in primary forms.
-
Membranous Nephropathy (MN):
- Pathophysiology: Immune complex deposition (often IgG antibodies against phospholipase A2 receptor [PLA2R] in primary MN) in the subepithelial space of the glomerular basement membrane (GBM), leading to thickening of the GBM.
- Clinical Presentation: Most common cause of nephrotic syndrome in non-diabetic adults. Presents with heavy proteinuria, edema.
- Prognosis: Spontaneous remission can occur, but many progress to ESRD. Treatment aims to reduce proteinuria and prevent progression.
-
IgA Nephropathy (Berger’s Disease):
- Pathophysiology: Deposition of IgA immune complexes in the mesangium of the glomeruli. Believed to be due to abnormal glycosylation of IgA1, leading to formation of immune complexes.
- Clinical Presentation: Most common primary glomerulonephritis worldwide. Often presents with recurrent macroscopic hematuria (especially after upper respiratory tract infections), or microscopic hematuria and proteinuria. Can be asymptomatic.
- Prognosis: Highly variable; some have benign course, others progress to ESRD.
-
Membranoproliferative Glomerulonephritis (MPGN) / C3 Glomerulopathy:
- Pathophysiology: Characterized by mesangial and endothelial cell proliferation, and GBM thickening. Can be immune complex-mediated (MPGN type I, II, III) or complement-mediated (C3 glomerulopathy, dense deposit disease).
- Clinical Presentation: Variable, can present as nephrotic syndrome, nephritic syndrome, or asymptomatic proteinuria/hematuria.
- Prognosis: Often progressive to ESRD.
42.3 Diagnostic Approach
Diagnosis of CGD requires a combination of clinical assessment, laboratory tests, and often a renal biopsy.
- Clinical Suspicion: Persistent proteinuria, hematuria, unexplained CKD, or features of nephrotic/nephritic syndrome.
- Laboratory Tests:
- Urinalysis: Proteinuria (quantified by urine protein-to-creatinine ratio or 24-hour urine protein), hematuria (dysmorphic red blood cells, red blood cell casts).
- Serum Creatinine/eGFR: To assess kidney function.
- Serum Albumin: To assess nutritional status and severity of nephrotic syndrome.
- Complement Levels (C3, C4): May be low in certain forms (e.g., MPGN, lupus nephritis).
- Autoantibodies: ANA, anti-dsDNA (lupus nephritis), ANCA (vasculitis), anti-GBM (Goodpasture syndrome), anti-PLA2R (primary MN).
- Infectious Serologies: Hepatitis B, C, HIV (can cause secondary CGD).
- Renal Biopsy: The gold standard for definitive diagnosis. Provides information on the specific type of glomerular injury, severity, chronicity, and guides treatment decisions. Light microscopy, immunofluorescence, and electron microscopy are used.
42.4 General Management Strategies
Management of CGD is complex and depends on the specific diagnosis, severity, and progression. It generally involves immunosuppression and supportive care.
Immunosuppressive Therapy:
- Corticosteroids: Often first-line for many immune-mediated CGD (e.g., FSGS, MN, IgA nephropathy with severe features).
- Cytotoxic Agents: Cyclophosphamide, mycophenolate mofetil (MMF), azathioprine (used in combination with steroids or as steroid-sparing agents).
- Calcineurin Inhibitors (CNIs): Cyclosporine, tacrolimus (effective in some forms of FSGS and MN).
- Rituximab: Anti-CD20 monoclonal antibody (used in some forms of MN, FSGS).
Supportive Care:
- Blood Pressure Control: Aggressive control (target <130/80 mmHg) with ACE inhibitors or ARBs to reduce proteinuria and slow CKD progression.
- Proteinuria Reduction: ACE inhibitors or ARBs are cornerstone therapy, even in normotensive patients, to reduce proteinuria and protect the kidneys.
- Edema Management: Diuretics and sodium restriction.
- Dyslipidemia Management: Statins to reduce cardiovascular risk.
- Dietary Modifications: Protein restriction (controversial), low sodium diet.
- Management of CKD Complications: Anemia, CKD-MBD, acidosis.
42.5 Prognosis and Long-Term Complications
The prognosis of CGD varies widely depending on the specific diagnosis, severity of proteinuria, degree of renal dysfunction at presentation, and response to therapy. Many forms can progress to ESRD, requiring dialysis or kidney transplantation. Long-term complications include accelerated cardiovascular disease, infections (due to immunosuppression), and malignancy.
Key Points on Chronic Glomerular Diseases
- Definition: Persistent inflammation and damage to glomeruli, leading to proteinuria, hematuria, hypertension, and CKD/ESRD.
- Common Types: FSGS (podocyte injury, nephrotic syndrome), Membranous Nephropathy (subepithelial immune complexes, nephrotic syndrome), IgA Nephropathy (mesangial IgA deposition, hematuria), MPGN/C3 Glomerulopathy (mesangial/endothelial proliferation, complement activation).
- Diagnosis: Clinical suspicion, urinalysis (proteinuria, hematuria), serologies (complement, autoantibodies), and definitive renal biopsy.
- Management: Immunosuppression (steroids, MMF, CNIs, rituximab) and aggressive supportive care (BP control with ACEi/ARBs, proteinuria reduction, edema management).
- Prognosis: Variable, often progressive to ESRD. Long-term complications include CVD and infections.
Chronic Glomerular Diseases Quick Guide
- Proteinuria/Hematuria: Red flags for glomerular disease.
- Biopsy is Key: Essential for definitive diagnosis and guiding treatment.
- ACEi/ARBs: Crucial for kidney protection, even in normotensives.
- Immunosuppression: Tailored to specific diagnosis.
- Long-term Follow-up: Essential due to risk of progression to ESRD.
Diagnostic Pearls
- Nephrotic vs. Nephritic: Differentiate based on clinical presentation (nephrotic: heavy proteinuria, edema; nephritic: hematuria, hypertension, renal dysfunction). Some CGD can present with features of both.
- Secondary Causes: Always consider secondary causes of CGD (e.g., diabetes, lupus, hepatitis, amyloidosis) before diagnosing a primary glomerulonephritis.
- Anti-PLA2R Antibody: A highly specific and sensitive marker for primary membranous nephropathy, often obviating the need for biopsy in typical cases.
Management Pearls
- Steroid Sparing Agents: In chronic conditions requiring long-term immunosuppression, steroid-sparing agents are crucial to minimize steroid-related side effects.
- Proteinuria as a Target: Reduction in proteinuria (e.g., by 50% from baseline) is a key therapeutic goal and a strong predictor of renal outcome in many CGD.
- Vaccinations: Ensure patients on immunosuppression are up-to-date on vaccinations (e.g., pneumococcal, influenza) to prevent severe infections.
Patient Education Pearls
- Disease Understanding: Educate patients about their specific type of CGD, its chronic nature, and the importance of adherence to medication and lifestyle changes.
- Monitoring: Emphasize the need for regular follow-up appointments and laboratory monitoring to track disease activity and medication side effects.
- Dietary Advice: Counsel on low-sodium diet for edema and hypertension, and appropriate protein intake based on disease stage.
Glomerular Disease Overview
Diagram illustrating the classification and general approach to glomerular diseases.
Key Diagrams
- Pathophysiology of FSGS: Diagram showing podocyte injury and segmental sclerosis.
- Immunofluorescence Patterns: Examples of different immune complex deposition patterns in various CGD.
- Renal Biopsy Algorithm: Flowchart for interpreting renal biopsy findings in CGD.
- Progression of CGD to ESRD: Illustration of the natural history and factors influencing progression.
Question 1
Which of the following is the most common cause of nephrotic syndrome in non-diabetic adults?
A) Focal Segmental Glomerulosclerosis (FSGS)
B) IgA Nephropathy
C) Membranous Nephropathy
D) Minimal Change Disease
Answer: C) Membranous Nephropathy
Explanation: Membranous nephropathy is the leading cause of nephrotic syndrome in non-diabetic adult patients.
Question 2
Which of the following is the most common primary glomerulonephritis worldwide, often presenting with recurrent macroscopic hematuria after an upper respiratory tract infection?
A) Membranous Nephropathy
B) Focal Segmental Glomerulosclerosis (FSGS)
C) IgA Nephropathy
D) Post-infectious Glomerulonephritis
Answer: C) IgA Nephropathy
Explanation: IgA nephropathy is characterized by recurrent episodes of macroscopic hematuria, typically following an infection, and is the most common primary glomerulonephritis globally.
Question 3
Which of the following serological markers is highly specific for primary membranous nephropathy?
A) Anti-dsDNA antibody
B) Anti-neutrophil cytoplasmic antibody (ANCA)
C) Anti-phospholipase A2 receptor (PLA2R) antibody
D) Anti-glomerular basement membrane (GBM) antibody
Answer: C) Anti-phospholipase A2 receptor (PLA2R) antibody
Explanation: Anti-PLA2R antibody is a highly specific and sensitive biomarker for primary membranous nephropathy, aiding in diagnosis and monitoring.
Question 4
In the management of chronic glomerular diseases, which class of medications is crucial for reducing proteinuria and slowing the progression of CKD, even in normotensive patients?
A) Loop diuretics
B) Beta-blockers
C) Calcium channel blockers
D) ACE inhibitors or ARBs
Answer: D) ACE inhibitors or ARBs
Explanation: ACE inhibitors and ARBs reduce intraglomerular pressure and proteinuria, providing renoprotective effects independent of their blood pressure-lowering effects.
Question 5
A renal biopsy is performed in a patient with nephrotic syndrome. Light microscopy shows segmental sclerosis and hyalinosis, while immunofluorescence is negative. Which diagnosis is most consistent with these findings?
A) Membranous Nephropathy
B) IgA Nephropathy
C) Focal Segmental Glomerulosclerosis (FSGS)
D) Membranoproliferative Glomerulonephritis (MPGN)
Answer: C) Focal Segmental Glomerulosclerosis (FSGS)
Explanation: FSGS is characterized by focal and segmental sclerosis on light microscopy, often with negative immunofluorescence in primary forms.
Question 6
Which of the following is a common long-term complication of chronic glomerular diseases?
A) Hypokalemia
B) Accelerated cardiovascular disease
C) Hypercalcemia
D) Acute liver failure
Answer: B) Accelerated cardiovascular disease
Explanation: Patients with chronic kidney disease, including those from CGD, have a significantly increased risk of cardiovascular morbidity and mortality.
Question 7
Which of the following is a key feature that differentiates nephrotic syndrome from nephritic syndrome?
A) Presence of hematuria
B) Presence of hypertension
C) Presence of heavy proteinuria (>3.5 g/day)
D) Presence of red blood cell casts
Answer: C) Presence of heavy proteinuria (>3.5 g/day)
Explanation: Heavy proteinuria (nephrotic range) is the hallmark of nephrotic syndrome, while hematuria, hypertension, and red blood cell casts are characteristic of nephritic syndrome.
Question 8
Which of the following is a common secondary cause of chronic glomerular disease?
A) Primary IgA nephropathy
B) Primary membranous nephropathy
C) Diabetes mellitus
D) Primary FSGS
Answer: C) Diabetes mellitus
Explanation: Diabetic nephropathy is a very common secondary cause of glomerular disease, leading to glomerulosclerosis.
Question 9
In a patient with suspected chronic glomerular disease, which of the following laboratory findings would most strongly suggest an immune-mediated process?
A) Elevated serum creatinine
B) Low serum albumin
C) Low C3 complement level
D) Presence of granular casts in urine
Answer: C) Low C3 complement level
Explanation: Low complement levels (especially C3) suggest activation of the complement system, which is involved in the pathogenesis of several immune-mediated glomerular diseases like MPGN or lupus nephritis.
Question 10
Which of the following is a crucial supportive care measure in the management of chronic glomerular diseases, aimed at reducing proteinuria and protecting kidney function?
A) High protein diet
B) Aggressive fluid loading
C) Strict blood pressure control with ACE inhibitors/ARBs
D) Avoidance of all diuretics
Answer: C) Strict blood pressure control with ACE inhibitors/ARBs
Explanation: Aggressive blood pressure control, particularly with ACE inhibitors or ARBs, is vital for reducing proteinuria and slowing the progression of kidney damage in CGD.
🎤 POWERPOINT PRESENTATION
[Link to interactive presentation slides covering all Chronic Glomerular Diseases concepts with visual aids and animations]
Slide Outline:
- Title Slide: Chronic Glomerular Diseases – Understanding and Managing Long-Term Kidney Injury
- Learning Objectives: What students will master
- Introduction: Definition, Classification (Primary vs. Secondary)
- Focal Segmental Glomerulosclerosis (FSGS): Pathophysiology, Clinical Features, Prognosis
- Membranous Nephropathy (MN): Pathophysiology, Clinical Features, Diagnosis (PLA2R), Prognosis
- IgA Nephropathy: Pathophysiology, Clinical Features, Prognosis
- Membranoproliferative Glomerulonephritis (MPGN) / C3 Glomerulopathy: Pathophysiology, Clinical Features
- Diagnostic Approach: Clinical Suspicion, Laboratory Tests (Urinalysis, Serologies), Renal Biopsy
- General Management Strategies: Immunosuppression (Corticosteroids, MMF, CNIs, Rituximab)
- Supportive Care: BP Control (ACEi/ARBs), Proteinuria Reduction, Edema, Dyslipidemia
- Prognosis and Complications: Progression to ESRD, Cardiovascular Risk, Infections
- Clinical Pearls: Diagnostic, Management, and Patient Education Tips
- Summary: Key Takeaways for Chronic Glomerular Diseases
- Assessment: Quick review questions
This educational content is original material created for NephroHub, synthesizing established knowledge on Chronic Glomerular Diseases while respecting all copyright considerations. All images are properly licensed or created specifically for educational use.
Visual Learning Workflow
